Ohio EPA fines Hikma Pharmaceuticals in Columbus $4,400 for violating hazardous waste laws - dispatch.com
Hikma Pharmaceuticals fined $4,400 by Ohio EPA for hazardous waste law violations.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 7, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers operating in Ohio, particularly those handling hazardous waste. should confirm how it applies to their specific situation before acting. There is a time constraint attached: as soon as possible. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Imposition of a $4,400 fine for non-compliance with hazardous waste regulations.
Who it affects
All pharmaceutical manufacturers operating in Ohio, particularly those handling hazardous waste.
What you must do
Review hazardous waste management practices to ensure compliance with Ohio EPA regulations.
Deadline
as soon as possible
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- High Court Decision on Arkansas PBM Law, ERISA Opens Door to State Laws - Bloomberg Law News
- Pharma loses a court battle in its bid to block states from importing drugs from Canada - statnews.com
- FDA on the Offense! Targeting Pharmaceutical Company Drug Advertising in Wave of Enforcement Actions - natlawreview.com
- FDA review details use of manufacturing process models in drug applications - RAPS
- House Republican introduces bill that would essentially nullify Nessel’s insulin price gouging suit - michiganadvance.com